^
    Back
    Association details:
    Biomarker:RAS mutation
    Cancer:Rhabdomyosarcoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    ganitumab (AMG 479) (IGF-1R inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models

    Published date:
    11/02/2022
    Excerpt:
    Treatment with trametinib and ganitumab resulted in synergistic cellular growth inhibition in all cell lines tested and inhibition of tumor growth in four out of six models of RAS-mutant RMS....We demonstrate that combined trametinib and ganitumab is effective in a genomically diverse panel of RAS-mutated FN RMS preclinical models.
    DOI:
    https://doi.org/10.1158/1078-0432.CCR-22-1646